Thursday 31 October 2019

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease - European Journal of Cancer

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease - European Journal of Cancer: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non–small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.

Highlights:
  • The majority aimed to cure sOM NSCLC patients.
  • The maximum number of metastases considered in sOM-d was 42% ≤ 3 and 17% ≥ 5.
  • Most considered only ≤3 involved organs (excluding primary).
  • Few counted mediastinal lymph node as a metastatic site.
  • The preferred primary outcome for sOM clinical trials was overall survival.
Bibliographic reference: Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019;122:109-114. Available at: https://doi.org/10.1016/j.ejca.2019.09.012.

Sunday 13 October 2019

Charlson comorbidity index (CCI)

It predicts 10-year survival in patients with multiple comorbidities.
Bibliographic reference: Charlson Comorbidity Index (CCI) - MDCalc [Internet]. Mdcalc.com. [cited 2019 Oct 13]. Available from: https://www.mdcalc.com/charlson-comorbidity-index-cci#use-cases.